UPSHER SMITH LABS
GenericsUPSHER SMITH LABS is a generic drug manufacturer focused on Neurology, Cardiovascular, Dermatology. Key products include QUDEXY XR.
UPSHER SMITH LABS at a Glance
- Strong track record with 92% execution quality across 5 trials
UPSHER SMITH LABS's Key Drugs
UPSHER SMITH LABS's core commercial portfolio centers on QUDEXY XR, CIPROFLOXACIN AND DEXAMETHASONE, VOGELXO, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Epilepsy
Acute Otitis Media
Primary Hypogonadism
Glaucoma
Acne
UPSHER SMITH LABS's Recent FDA Approvals
New NDA/BLA approvals for UPSHER SMITH LABS over the last two years — novel drugs only, excluding generics and label supplements.
UPSHER SMITH LABS's Therapeutic Areas
UPSHER SMITH LABS's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UPSHER SMITH LABS's Top Competitors
UPSHER SMITH LABS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UPSHER SMITH LABS Pipeline Snapshot
UPSHER SMITH LABS has 4 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • QUDEXY XR leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/2 completed
- • Speed: 37 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (5)
Discontinued (0)
Company Info
- First Approval
- 1974-07-09
- Latest
- 2026-06-18
- Applications
- 88
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges